Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol in refractory childhood epilepsy, a personalized high-quality approach
2023-507843-12-01Phase 3Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in epilepsy (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Change from baseline in daily seizure frequency. Planned start Aug 2024; status: authorised.
02
Drugs
cannabidiol
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2023-507843-12-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507843-12-01.